Home> Latest

Pudong's innovative drugs accelerate global expansion

english.pudong.gov.cn Updated:2026-07-06

Pudong's biopharmaceutical sector is gaining global momentum, with innovative medicines making breakthroughs in patient care and overseas markets. China's first approved CAR-T cell therapy product, Yescarta® (axicabtagene ciloleucel), has treated more than 1,500 patients in five years.

图片20.png

A researcher works on drug development experiments at a biopharmaceutical laboratory. [Photo/WeChat ID: pdnews]

Developed by Fosun Kite Biotechnology, Yescarta® is now available at more than 200 treatment centers across China, marking a major milestone in the country's transition from pioneering cell therapy to broader clinical adoption.

Shanghai Henlius Biotech, Inc. has expanded the global reach of its innovative biopharmaceutical products, with its denosumab injections BILDYOS® and TUZEMTY® commercially launched in Canada, covering all approved indications of reference products PROLIA® and XGEVA®.

Shanghai Yinnuo Pharmaceutical Technology Co Ltd. has received approval from China's National Medical Products Administration (NMPA) to initiate a Phase Ib clinical trial of its long-acting GLP-1 receptor agonist efsubaglutide alfa injection for weight management in adolescents.

As a major hub for Shanghai's biopharmaceutical industry, Pudong has developed a full-chain innovation ecosystem covering research, incubation, clinical translation, and commercialization, accelerating the development of a world-class biopharmaceutical cluster.